Compare Dicks Sporting Goods Inc (DKS) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs DexCom, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $203.03 (market cap $18.35B), while DexCom, Inc. trades at $89.44 (market cap $33.79B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DKS | DXCM | |
|---|---|---|
Market Cap | $18.35B | $33.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $89.53 |
52-Week Low | $187.78 | $54.84 |
Enterprise Value | $25.14B | $33.24B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $201.95, down 5.67% in the past 24 hours, with technical indicators showing a bearish trend and key support at $198. Fundamentally, the company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.90 beating expectations, and maintains solid profitability with a 32.21% gross margin and 20.9% ROE. Recent news highlights analyst upgrades and positive coverage, while the company announced a $1.25 dividend payable in June 2026.
The outlook for DKS is mixed; analyst consensus is bullish with a $263.22 price target and no sell ratings, but technical weakness and a recent decline pose near-term risks. Investment opportunities include undervaluation based on a P/E of 19.96 and accelerating sales growth, while risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder litigation news.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
